Net revenue for pharmaceutical giant Mylan N.V. rose 4% to $3.16 billion for the three months ending Dec. 31, up from $3.04 billion a year ago, topping analysts’ predictions for the quarter.

In its last full-year earnings report as a standalone company, Mylan — which has corporate offices in Cecil and Hertfordshire, England — reported total revenue of $3.19 billion for the three months, up 4% from a year ago.

Earnings per share for the period were 4 cents, which compared to 10 cents per share for the fourth quarter of 2018.

Thomson Reuters Corp. had forecast earnings of $1.28 for the quarter, and Mylan beat the estimate by returning $1.40 per share. Net sales for each of the drugmaker’s units rose between 3% and 9% for the period.

Advertise with us

Mylan shares closed Thursday down 86 cents at $18.68.

In a conference call with investors after the markets closed Thursday, CEO Heather Bresch said the company’s business exposure in China, where the COVID-19 outbreak is centered, was limited. “However, given the global nature of our supply chain, operations and businesses, our results could potentially be impacted” in the coming months, she said.

Still, the company’s top 20 or 25 products are not dependent on China at all, Mylan President Rajiv Malik told investors.

The company is forecasting total revenue as a standalone company between $11.5 billion and $12.5 billion for 2020, a 4% increase from mid-2019. Mylan is no longer providing earnings per share guidance.

In July, Mylan announced plans to merge with Pfizer’s Upjohn unit, which includes off-patent, branded and generic business. The deal, which will create a company to be called Viatris, is expected to be completed by mid-2020, when Ms. Bresch, 50, the first female CEO of a Fortune 500 pharmaceutical company, will retire.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699